

Editor: Frederick L. Kiechle, MD, PhD

Submit your pathology-related question for reply by appropriate medical consultants. CAP TODAY will make every effort to answer all relevant questions. However, those questions that are not of general interest may not receive a reply. For your question to be considered, you must include your name and address; this information will be omitted if your question is published in CAP TODAY.

Q. Some recent clinical guidelines recommend lower therapeutic and toxic limits for digoxin than those provided in assay package inserts. What therapeutic ranges and toxic thresholds should laboratories use?

A. September 2023—The CAP General Chemistry and Therapeutic Drug Monitoring Survey program includes therapeutic drugs that have been in use for decades and for which numerous commercial assays are available. The serum/plasma concentrations of some drugs, such as acetaminophen, salicylate, and vancomycin, are frequently measured to assess for toxicity or as part of therapeutic drug monitoring, while other drugs, such as digoxin, are less frequently prescribed today and, therefore, less frequently assessed.

Once a mainstay for treating atrial fibrillation and heart failure, digoxin has largely been supplanted by newer medications. Because of its infrequent clinical use, health care providers and clinical laboratories may become less familiar with therapeutic drug monitoring of digoxin. However, it retains limited indications despite being widely recognized as a potentially toxic compound. More than 3,000 participants in the Survey program report digoxin measurements, on par with the number who report acetaminophen, salicylate, and vancomycin measurements.

While early studies suggested digoxin concentrations up to 2.0–2.5 ng/mL (2.6–3.2 nmol/L) were tolerable, recognition of toxicity risk at lower concentrations has led to support for lowering the upper therapeutic limit to 0.9–1.2 ng/mL (1.2–1.5 nmol/L).¹ Recent large trials and clinical guidelines also advocate lowering digoxin therapeutic ranges. These include the ARISTOTLE trial in atrial fibrillation² and the 2022 heart failure guidelines from the American Heart Association, American College of Cardiology, and Heart Failure Society of America.³

Despite concerns about risks for toxicity, recent studies support decreasing (e.g. to 0.5 ng/mL [0.6 nmol/L]) or eliminating (e.g. therapeutic range <1.0 ng/mL [<1.3 nmol/L]) the lower limit of the therapeutic range. In contrast, previous recommendations were often ≥0.8 ng/mL (≥1.0 nmol/L). Inappropriate lower limits could lead providers who are unfamiliar with digoxin management to raise doses to address perceived subtherapeutic concentrations.

Unfortunately, guidelines and clinical trials rarely address the assays used to measure digoxin or mention such issues as lack of assay standardization, evolution of methodologies, and variable influence of interfering substances.⁴ A 2013 survey of 60 laboratories found that most had upper therapeutic limits set between 2.0 and 2.5 ng/mL (2.6 and 3.2 nmol/L), reflecting older recommendations.¹ As there is little incentive for assay manufacturers to update product information, digoxin therapeutic ranges given in package inserts might not be based on recent studies or guidelines.

All laboratories performing digoxin testing are encouraged to evaluate their test performance and patient demographics, in collaboration with cardiology and other relevant clinical practices, to determine the appropriate therapeutic range for their unique population.

1. Hauptman PJ, McCann P, Ramirez Romero JM, Mayo M. Reference laboratory values for digoxin following

- publication of Digitalis Investigation Group (DIG) trial data. *JAMA Intern Med.* 2013;173(16):1552–1554.
2. Lopes RD, Rordorf R, De Ferrari GM, et al; ARISTOTLE Committees and Investigators. Digoxin and mortality in patients with atrial fibrillation. *J Am Coll Cardiol.* 2018;71(10):1063–1074.
 3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2022;79(17):e263–e421.
 4. Dasgupta A. Significant improvement in digoxin immunoassays over four decades: newer assays are less affected by interferences. *Ther Drug Monit.* 2023;45(1):26–34.

Christine Snozek, PhD, D(ABCC)
Codirector, Clinical Chemistry and Support Services
Director, Point of Care and Central Processing
Mayo Clinic Arizona
Phoenix, Ariz.
Member, CAP Toxicology Committee

Matthew David Krasowski, MD, PhD
Clinical Professor of Pathology
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Chair, CAP Toxicology Committee

Q. One of our providers noticed that two laboratories—one in New York and one in Florida—reported very different thyroid-stimulating hormone values for a patient and called our laboratory to determine which was correct. How should we handle such situations?


A. Differences among laboratories in reported thyroid-stimulating hormone (TSH) values and testing methods used on the same patient or even the same sample are not surprising. The most important factors that cause these differences are standardization and calibration bias, differences in specificity among methods, and differences in reference populations.

Standardization and calibration bias. In a CAP study, published in 2005, that used fresh frozen human serum, 17 TSH methods had mean differences of up to 0.48 mU/L at an average TSH level of 1.46 mU/L, or a difference as high as 39 percent when comparing the method with the highest values to that with the lowest values.¹ A 2010 report from the IFCC Working Group for Standardization of Thyroid Function Tests similarly showed a broad range of differences among 16 immunoassays for TSH, using a panel of 40 human samples.² In the IFCC study, the most discrepant TSH testing methods differed by an average of 39 percent, similar to the findings reported by the CAP in 2005.¹ The IFCC Working Group noted that in view of these findings, harmonization of TSH testing methods may be

beneficial, particularly in light of contemporary clinical practice guidelines proposing to lower the TSH clinical decision limit.³

Despite ongoing standardization efforts, recent data from the CAP Accuracy-Based Programs (**figure**) demonstrate that when using pooled human serum specimens to compare testing methods, differences in standardization have been consistent and persistent.

Figure. Biases Among Thyroid-Stimulating Hormone Immunoassay Methods



TSH results from the CAP Accuracy-Based Programs ABS Survey, 2021-2022 (N=12 specimens). For 12 challenge specimens (distributed as three specimens per challenge every six months over two years), the box plot shows the distribution of percent biases to the all-methods median among five test methods for which peer groups could be assigned (based on sufficient numbers of participant laboratories). For each test method, in addition to mean %bias (represented by an X), each box provides five horizontal lines along a vertical axis representing (from lowest to highest, respectively) minimum %bias, %bias at 25th percentile, %bias at median, %bias at 75th percentile, and maximum %bias. For one test method (Abbott Alinity), a small dot (°) is shown below the box to represent an outlier value that was removed prior to calculation of the respective %bias percentiles.

Differences in specificity among methods. A 2013 article by Faix and Thienpont described the current state of the art and challenges in measuring TSH.⁴ In particular, the authors highlighted the role of molecular heterogeneity in TSH measurement. They reported that the pituitary gland releases a heterogeneous mixture of TSH glycoforms, an array of unique molecules with various carbohydrate side chains. This high degree of molecular heterogeneity, especially with respect to glycosylation, contributes to a broad range of measurable epitopes. Since immunoassays employ a variety of monoclonal antibodies, each type varying in its ability to detect TSH epitopes, the amount of TSH measured in a clinical sample by a given testing method depends not only on the testing method's standardization but also on the selection of monoclonal antibodies in the manufacturer's reagent kit. This variability can potentially lead to different TSH results across methods used on the same samples, even with well-standardized TSH testing methods. In addition to variability in specificity due to differences in selectivity for TSH epitopes, discrepant TSH values may be attributable to interference from autoantibodies or macro-TSH.⁵

Differences in reference populations. TSH reference intervals also vary among testing methods.⁶ The TSH reference interval defined by each manufacturer is sensitive to the manufacturer's selection of individuals included in the reference population. Including certain subgroups may skew the high end of the distribution, making it non-

Gaussian. Including older adults, in whom higher TSH levels are often observed, is one example. People with obesity compose another subgroup that typically has higher TSH values, unrelated to thyroid function.

Until TSH test methods are harmonized, laboratories should exercise caution when comparing results from different TSH testing methods. And when practicable, the same testing method should be used each time when monitoring a patient known to have thyroid disease.

1. Steele BW, Wang E, Klee GG, et al. Analytic bias of thyroid function tests: analysis of a College of American Pathologists fresh frozen serum pool by 3900 clinical laboratories. *Arch Pathol Lab Med*. 2005;129(3):310-317.
2. Thienpont LM, Van Uytvanghe K, Beastall G, et al. Report of the IFCC Working Group for Standardization of Thyroid Function Tests; part 1: thyroid-stimulating hormone. *Clin Chem*. 2010;56(6):902-911.
3. Demers LM, Spencer CA, eds. *Laboratory Medicine Practice Guidelines: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease*. National Academy of Clinical Biochemistry; 2002.
4. Faix JD, Thienpont LM. Thyroid-stimulating hormone: why efforts to harmonize testing are critical to patient care. *Clinical Laboratory News*. May 1, 2013. <https://www.aacc.org/cln/articles/2013/may/tsh-harmonization>
5. Hattori N, Ishihara T, Shimatsu A. Variability in the detection of macro TSH in different immunoassay systems. *Eur J Endocrinol*. 2016;174(1):9-15.
6. Barth JH, Luvai A, Jassam N, et al. Comparison of method-related reference intervals for thyroid hormones: studies from a prospective reference population and a literature review. *Ann Clin Biochem*. 2018;55(1):107-112.

Neil Greenberg, PhD, DABCC

Principal Consultant

Neil Greenberg Consulting Services LLC

Rochester, NY

Member, IFCC Working Group on Commutability in Metrological Traceability

Member, CAP Accuracy-Based Programs Committee